Evidence map›Paper›PMID 31410203›Full record

ReviewTheranostics2019

Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Benjamin B Kasten, Neha Udayakumar, Jianmei W Leavenworth, Anna M Wu, Suzanne E Lapi, Jonathan E McConathy, Anna G Sorace, Asim K Bag, James M Markert, Jason M Warram

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. [Theranostics · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. PET/MRI Improves Management of Children with Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  16. Review
  17. [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benjamin B KastenDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States.
Neha UdayakumarSchool of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Jianmei W LeavenworthDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States.
Anna M WuCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States.
Suzanne E LapiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Jonathan E McConathyDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Anna G SoraceDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Asim K BagDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, United States.
James M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States.
Jason M WarramDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, United States.

Funding

Training Program in Brain Tumor BiologyT32NS048039 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BENVENISTE, ETTY N · 2007 to 2017
$2.0M
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma PatientsR01CA222903 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CASSADY, KEVIN A, MARKERT, JAMES M · 2018 to 2020
$1.7M
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.R01CA217179 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY, MARKERT, JAMES M · 2017 to 2019
$1.6M
NCI NIH HHS R01 CA217179NCI NIH HHS R01 CA222903NINDS NIH HHS T32 NS048039
6 · The paper itself

Abstract

Imaging plays a central role in evaluating responses to therapy in neuro-oncology patients. The advancing clinical use of immunotherapies has demonstrated that treatment-related inflammatory responses mimic tumor growth via conventional imaging, thus spurring the development of new imaging approaches to adequately distinguish between pseudoprogression and progressive disease. To this end, an increasing number of advanced imaging techniques are being evaluated in preclinical and clinical studies. These novel molecular imaging approaches will serve to complement conventional response assessments during immunotherapy. The goal of these techniques is to provide definitive metrics of tumor response at earlier time points to inform treatment decisions, which has the potential to improve patient outcomes. This review summarizes the available immunotherapy regimens, clinical response criteria, current state-of-the-art imaging approaches, and groundbreaking strategies for future implementation to evaluate the anti-tumor and immune responses to immunotherapy in neuro-oncology applications.

Indexed as

AnimalsHumansImmunotherapyMagnetic Resonance ImagingNervous System NeoplasmsPositron-Emission TomographyTheranostic NanomedicineimagingimmunotherapyMRIneuro-oncologyPETresponse

Identifiers

PMID31410203
PMCPMC6691392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.